Keros Therapeutics, Inc.
As of Oct 22, 2026, Keros Therapeutics is in Stage 1, the basing phase, now in week 8 (since Aug 28, 2026). It closed at $11.35, 48.0% below its 52-week high and below its 200-day average, which is falling.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transform… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is KROS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
KROS among Biotechnology268th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …268 | KROS | Stage 1 · wk 8 | 35 | −2.4% |
Keros Therapeutics: quick answers
What stage is Keros Therapeutics in?
As of Oct 22, 2026, Keros Therapeutics (KROS) is in Stage 1, the basing phase. It entered Stage 1 on Aug 28, 2026 and is in week 8. What the four stages mean
Is Keros Therapeutics in an uptrend?
Not yet. Keros Therapeutics is in Stage 1, a base that can come before an uptrend. It trades 7.7% below its 200-day average, which is falling.
How far is Keros Therapeutics from its 52-week high?
Keros Therapeutics closed at $11.35 on Oct 22, 2026, 48.0% below its 52-week high of $21.84. Its 52-week low is $9.91.
How has Keros Therapeutics performed over the past year?
As of Oct 22, 2026, Keros Therapeutics is down 26.3% over the past year and down 38.8% so far in 2026.
Which sector and industry is Keros Therapeutics in?
Keros Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.